Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asterias Biotherapeutics

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

- PMLiVE

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects

- PMLiVE

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

Ends AZ’s main challenge to Keytruda for first-line use

- PMLiVE

Tagrisso tops rival drugs on survival in first-line lung cancer

Takes fight to Pfizer's Vizimpro

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Envision appoints new patient partnerships leader

Joins from Cancer Research UK

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Keytruda adds another NSCLC approval in Europe

Squamous NSCLC completes first-line dominance

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

Neoantigen player Achilles gets OK for first clinical trial

Will test the candidate in advanced NSCLC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links